Wegovy, a GLP-1 receptor agonist, slows gastric emptying, which can contribute to constipation
GHK-Cu builds collagen, TB-500 delivers repair cells where they are needed, and BPC-157 reduces inflammation and protects the gut
Europe represents the second-largest GLP-1 market region with 19.4% revenue share and 13.8% CAGR
Improvement in RLS symptoms may take several weeks to months following iron repletion
10.1016/s0014-2999(01)01252-3 23 Hyltn-CavalliusL.IepsenE
Here's how they compare: Semaglutide (GLP-1 agonist) Mechanism: Single-action GLP-1 receptor agonist FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: 15-20% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients starting their weight loss journey seeking proven, well-studied medication Tirzepatide (dual GIP/GLP-1 agonist) Mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effect FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: Up to 22% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients seeking more aggressive fat loss with dual-action metabolic support Retatrutide (triple agonist, not yet available) Mechanism: Targets GLP-1, GIP, and glucagon receptors FDA status: Not FDA-approved
